Aprea Therapeutics
APRE
24 hedge funds and large institutions have $521K invested in Aprea Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
4,550% more call options, than puts
Call options by funds: $186K | Put options by funds: $4K
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.21% less ownership
Funds ownership: 0.36% → 0.15% (-0.21%)
8% less funds holding
Funds holding: 26 → 24 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
53% less capital invested
Capital invested by funds: $1.11M → $521K (-$589K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$26.9K |
| 2 |
Millennium Management
New York
|
+$22.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$13.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$6.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$54.5K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$40.2K |
| 3 |
Morgan Stanley
New York
|
-$19.1K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$13K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$13K |
APRE Hedge Fund Activity: Q4 2022 in Review
24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2022, worth a combined $521K — down 53% from $1.11M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of APRE and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Jane Street, opening a new position worth an estimated $26.9K. The largest seller was Renaissance Technologies, cutting an estimated $54.5K.
- 24 institutional investors held Aprea Therapeutics (APRE) as of Q4 2022, down from 26 in Q3 2022.
- Funds reported $521K of Aprea Therapeutics stock for Q4 2022, down 53% quarter-over-quarter.
- 3 funds opened new Aprea Therapeutics positions in Q4 2022 and 5 closed out, a net change of -2 holders.
- The largest Aprea Therapeutics buyer in Q4 2022 was Jane Street, an estimated $26.9K added.
- The largest Aprea Therapeutics seller in Q4 2022 was Renaissance Technologies, an estimated $54.5K sold.
Based on aggregated 13F filings for Q4 2022.